Atoncy Solution
NDC Package 30698-456-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Atoncy (atomoxetine hydrochloride) solution is aTONCY is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adult and pediatric patients 6 years of age and older. This formulation utilizes a solution delivery system. Marketed by Validus Pharmaceuticals Llc, this product is identified by NDC 30698-456 and is authorized under FDA application NDA220320.

Identification & Billing

NDC Package Code
30698-456-02
Package Description
1 BOTTLE, GLASS in 1 CARTON / 100 mL in 1 BOTTLE, GLASS
Product Code
30698-456
11-Digit Billing Format
30698045602
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Atoncy
Non-Proprietary Name
Atomoxetine Hydrochloride
Substance Name
Atomoxetine Hydrochloride
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ATOMOXETINE HYDROCHLORIDE 4 mg/mL
Pharmacologic Class
Usage Information
ATONCY is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adult and pediatric patients 6 years of age and older. ATONCY is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD.

Regulatory & Marketing

Labeler Name
Validus Pharmaceuticals Llc
Product Type
Human Prescription Drug
FDA Application #
NDA220320
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-20-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 30698-456-02 identifies a specific commercial package of 1 bottle, glass in 1 carton / 100 ml in 1 bottle, glass of Atoncy, a human prescription drug labeled by Validus Pharmaceuticals Llc. This solution is formulated for oral use and contains atomoxetine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Validus Pharmaceuticals Llc on March 20, 2026. The current certification is valid through December 31, 2027.

How is this Validus Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 30698045602. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
30698-456-02
11-Digit CMS (5-4-2)
30698-0456-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.